Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.

CONCLUSIONS: These post hoc analyses of a subgroup of patients demonstrate the continued therapeutic efficacy of aripiprazole lauroxil after successful treatment of an acute episode of schizophrenia. Both the 441 mg and 882 mg groups had similar retention rates, degree of symptom improvement, and likelihood of remission. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01469039; European Clinical Trials Database (EudraCT) numbers: 2012-003445-15 and 2012-003996-20. PMID: 28937706 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28937706?dopt=Abstract

Source: Journal of Clinical Psychiatry - September 23, 2017 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research